Herein, we demonstrate that NXP800, a heat shock factor 1 pathway inhibitor in clinical development, activates the unfolded protein response and inhibits AR- and E2F-mediated transcription as well as the growth of treatment-resistant prostate cancer models. This evidence concerns the gene AR and prostate carcinoma.